logo
I use this anti-aging eye cream daily and I look 10 years younger than I am — it's on sale for under $20

I use this anti-aging eye cream daily and I look 10 years younger than I am — it's on sale for under $20

Yahoo19 hours ago
Shoppers say it "reduced hyperpigmentation" and works "way better than expensive eye creams."
When I turned 40, with a baby on the way, it became much more challenging to conceal the puffy eyes and dark circles of a sleepless night. A few years later, I added another kiddo and tired eyes became my trademark look.
I tried dozens of products to revive the delicate under-eye area, but it wasn't until CeraVe's Eye Repair Cream that I actually started to notice long-term improvements. As someone with easily irritated eyes, this lightweight cream is my daily go-to. So, when my four-year-old is up at 3 a.m. with an ear infection, CeraVe's eye cream will help to hide the evidence of a sleepless night.
I'm not the only one who loves this affordable beauty product — according to our data, hundreds of Yahoo readers have also snapped it up. Read on to find out why I'm obsessed — and to shop it on sale for $19.
The details
This fragrance-free, ophthalmologist-tested eye cream contains three essential ceramides and hydrating hyaluronic acid. It's made with a patented delivery system that continually releases the ingredients so your eyes stay moisturized all day long. With continued regular use, you will notice a reduction in dark circles and under-eye puffiness.
Apply a few dots of the cream to your under-eye area in the morning and evening, and gently smooth until fully absorbed. It works great alone or under makeup.
The CeraVe eye cream, developed with dermatologists, is non-comedogenic and great for all skin types.
What I like about it
It's great for sensitive eyes: I love how the CeraVe cream moisturizes without irritating my sensitive eyes. It absorbs quickly and is a great primer for my under-eye concealer. Each application requires just a few dots of the product, so the little tube goes a long way.
Dermatologist-approved: I also appreciate that the product has been recognized by the Canadian Dermatology Association and has been well-tested by experts. It's not just some gimmicky eye cream but one that has a lot of science behind it, which matters to me.
Great for hyperpigmentation: With more than 3,600 reviews and a 4.3-star rating, it's clear I am not the only one who swears by this hydrating cream. One shopper said they wished they had found it sooner as it significantly "reduced hyperpigmentation" under their eyes. They stated that their under-eye area became 30 per cent lighter, which they say is a "big win."
Not greasy: Another reviewer mentions how "non-greasy" the cream is and that it doesn't irritate sensitive eyes, while another person calls it a "wonderful product."
$19 $24 at Amazon
Other mature beauty & fashion recommendations:
I'm a 48-year-old mom who loves shopping at Amazon — 12 summer tops I'm buying, all under $50
I tried on 13 Reitmans dresses on sale for under $75 — if you're in your 40s or 50s, these styles are seriously good
These viral Amazon eye masks help make my bags look 'less puffy' — and they're on sale right now
Room for improvement
It's not a quick-fix eye cream: This product is great, but it's not a fast-acting wonder cream. You need to use it for several weeks, if not months, to see any remarkable improvements. Also, you can't skip applications, or it will set your results back. Commit to using it for a solid six months before you assess if it's working for you.
Some Amazon reviewers mentioned they saw no visible difference after a few weeks; however, from personal experience, the cream takes time to do its thing. I promise, if you stick with it, your under-eye area will improve — just don't give up!
It's not as hydrating as other eye creams: The eye cream could be a tad thicker; however, it probably wouldn't absorb as well if it was. CeraVe has a unique formula that may take a while to work, but once it does, it's great. My advice? Don't throw in the towel just yet.
What reviewers are saying
With hundreds of five-star reviews, I am far from the only fan of CeraVe's Eye Repair Cream.
One reviewer, who has struggled with "hollow eyes" and "hyperpigmentation" their "whole life," says the eye cream has made their under-eye area "about 30 per cent lighter" — a "big win" for them.
They write that their dark eye bags are "barely noticeable" after applying makeup. "I will definitely be buying [it] again."
Another shopper agrees it's a "great cream for dark circles," adding that it works "way better than expensive eye creams."
"Every dollar spent on it is worth it," they write.
"My advice," echoes a third shopper: "Throw out all your expensive skin care" and only buy CeraVe products.
They're "reasonably priced," and, importantly, "they work."
Despite thousands of five-star reviews, some warn it's "not a miracle product" and agree it can take a few months to show noticeable results.
The verdict
I love CeraVe products, and this one is no exception. It's gentle on my eye area, and after using it for a few months straight, I saw significant improvements in my dark circles and under-eye puffiness.
That said, if you are looking for something to quickly erase a night out with the girls or a long overseas flight, this is probably not going to provide the quick fix you need. This lightweight cream will yield results, but it's going to take some time. If you commit to using it twice a day for the next six months, I'm certain you will be impressed with what you see (and don't see) under your eyes in the morning.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

UnitedHealth appoints Wayne DeVeydt as CFO in another management shake-up
UnitedHealth appoints Wayne DeVeydt as CFO in another management shake-up

Yahoo

time12 minutes ago

  • Yahoo

UnitedHealth appoints Wayne DeVeydt as CFO in another management shake-up

(Reuters) -UnitedHealth said on Thursday it will replace its finance chief John Rex with an external hire, Wayne DeVeydt, adding to the management changes at the health insurer that has been struggling to control its medical costs. Rex, who has been handling the role since 2016, will continue as a strategic advisor to the CEO, with the changes effective September 2. DeVeydt was most recently managing director and operating partner at Bain Capital, and was also the finance chief of UnitedHealth's rival Elevance , then called Anthem, between 2007 and 2016. The largest U.S. health insurer had seen an abrupt departure of Andrew Witty as CEO in May, with Stephen Hemsley replacing him following struggles with elevated medical costs that were also seen in the rest of the industry. Hemsley is under pressure to regain investor trust as the company faces financial struggles and reputational damage that surfaced after the then-CEO of its health insurance unit was gunned down on a New York City street in December. Sign in to access your portfolio

ResMed (NYSE:RMD) Surprises With Q2 Sales
ResMed (NYSE:RMD) Surprises With Q2 Sales

Yahoo

time12 minutes ago

  • Yahoo

ResMed (NYSE:RMD) Surprises With Q2 Sales

Medical device company ResMed (NYSE:RMD) beat Wall Street's revenue expectations in Q2 CY2025, with sales up 10.2% year on year to $1.35 billion. Its non-GAAP profit of $2.55 per share was 3% above analysts' consensus estimates. Is now the time to buy ResMed? Find out in our full research report. ResMed (RMD) Q2 CY2025 Highlights: Revenue: $1.35 billion vs analyst estimates of $1.33 billion (10.2% year-on-year growth, 1.3% beat) Adjusted EPS: $2.55 vs analyst estimates of $2.48 (3% beat) Adjusted EBITDA: $542.9 million vs analyst estimates of $494.7 million (40.3% margin, 9.8% beat) Operating Margin: 33.7%, up from 31.2% in the same quarter last year Free Cash Flow Margin: 37.7%, up from 33.9% in the same quarter last year Constant Currency Revenue rose 9% year on year (10% in the same quarter last year) Market Capitalization: $40.61 billion 'Our strong finish to fiscal year 2025 reflects ongoing momentum across our business, driven by robust global demand for our market-leading sleep and breathing health devices, as well as our expanding digital health ecosystem,' said Resmed's Chairman and CEO, Mick Farrell. Company Overview Founded in 1989 to address the then-underdiagnosed condition of sleep apnea, ResMed (NYSE:RMD) develops cloud-connected medical devices and software solutions that treat sleep apnea, COPD, and other respiratory disorders for home and clinical use. Revenue Growth A company's long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Luckily, ResMed's sales grew at a decent 11.7% compounded annual growth rate over the last five years. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. ResMed's annualized revenue growth of 10.4% over the last two years is below its five-year trend, but we still think the results were respectable. ResMed also reports sales performance excluding currency movements, which are outside the company's control and not indicative of demand. Over the last two years, its constant currency sales averaged 10.3% year-on-year growth. Because this number aligns with its normal revenue growth, we can see that ResMed has properly hedged its foreign currency exposure. This quarter, ResMed reported year-on-year revenue growth of 10.2%, and its $1.35 billion of revenue exceeded Wall Street's estimates by 1.3%. Looking ahead, sell-side analysts expect revenue to grow 8.1% over the next 12 months, a slight deceleration versus the last two years. Despite the slowdown, this projection is noteworthy and suggests the market is forecasting success for its products and services. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Operating Margin ResMed has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average operating margin of 29%. Analyzing the trend in its profitability, ResMed's operating margin rose by 4.5 percentage points over the last five years, as its sales growth gave it operating leverage. This performance was mostly driven by its recent improvements as the company's margin has increased by 5.9 percentage points on a two-year basis. These data points are very encouraging and shows momentum is on its side. This quarter, ResMed generated an operating margin profit margin of 33.7%, up 2.6 percentage points year on year. This increase was a welcome development and shows it was more efficient. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. ResMed's EPS grew at a spectacular 14.9% compounded annual growth rate over the last five years, higher than its 11.7% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded. We can take a deeper look into ResMed's earnings to better understand the drivers of its performance. As we mentioned earlier, ResMed's operating margin expanded by 4.5 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its higher earnings; interest expenses and taxes can also affect EPS but don't tell us as much about a company's fundamentals. In Q2, ResMed reported adjusted EPS at $2.55, up from $2.08 in the same quarter last year. This print beat analysts' estimates by 3%. Over the next 12 months, Wall Street expects ResMed's full-year EPS of $9.55 to grow 8.6%. Key Takeaways from ResMed's Q2 Results It was good to see ResMed narrowly top analysts' revenue expectations this quarter. We were also happy its constant currency revenue narrowly outperformed Wall Street's estimates. Overall, this print had some key positives. The stock remained flat at $270.94 immediately following the results. So do we think ResMed is an attractive buy at the current price? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Childhood Vaccination Rates Have Dropped Again, C.D.C. Data Shows
Childhood Vaccination Rates Have Dropped Again, C.D.C. Data Shows

New York Times

time15 minutes ago

  • New York Times

Childhood Vaccination Rates Have Dropped Again, C.D.C. Data Shows

New federal data shows that vaccination rates among American children entering kindergarten fell during the 2024-25 school year, extending a worrying trend that began during the Covid-19 pandemic. The percentage of children granted exemptions from vaccines has also risen sharply over the past decade. The statistics, released Thursday by the Centers for Disease Control and Prevention, provide a sobering explanation for the resurgence of childhood diseases across the United States. Measles has sickened more people this year than in any year since the virus was declared eliminated in 2000, in large part because of a multistate outbreak that began in West Texas and has led to three deaths. 'The more these rates continue to drop, the more danger we're in of seeing outbreaks like we saw in Texas,' said Dr. Adam Ratner, a pediatric infectious disease expert in New York City. The report comes at a time when public health experts are particularly concerned about childhood vaccinations because of increasing skepticism of the shots, including among top health officials. Robert F. Kennedy Jr., the health secretary, has questioned, without scientific basis, the safety of many childhood vaccines, including those for measles, hepatitis B and polio. In June, a panel of vaccine advisers installed by Mr. Kennedy announced that they would closely scrutinize the immunization schedules for children and adolescents. Mr. Kennedy's appointees have also restricted access to the Covid-19 vaccine for healthy pregnant women and children. The messaging from Mr. Kennedy's office seems 'specifically designed to sow distrust in vaccines,' said Dr. Sean O'Leary, chair of the infectious disease committee for the American Academy of Pediatrics. Source: Centers for Disease Control and Prevention Note: Data is incomplete for Mississippi, Montana and West Virginia. Source: Centers for Disease Control and Prevention Want all of The Times? Subscribe.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store